Cytek Biosciences, Inc. is a pioneering cell analysis solutions company committed to advancing the next generation of cell analysis. Their core technology, Full Spectrum Profiling™ (FSP™), powers their flagship Aurora and Northern Lights™ systems, enabling scientists to extract more comprehensive data from fewer samples with higher resolution and sensitivity. Cytek's instruments and reagents are utilized across diverse research fields including immunology, oncology, infectious diseases, and more, driving deeper biological insights and accelerating scientific discovery. They focus on providing accessible, powerful tools to researchers worldwide.
The Fremont headquarters serves as the central hub for Cytek's global operations, including research and development, manufacturing, global marketing, sales leadership, and corporate administration.
State-of-the-art facilities designed for advanced research, precision manufacturing of complex cytometric instrumentation, and collaborative workspaces.
The work culture at Cytek's HQ is characterized by innovation, collaboration, and a strong focus on scientific excellence. Employees are driven by the mission to empower researchers with cutting-edge cell analysis tools.
Its location in Silicon Valley provides access to a rich talent pool, technological partnerships, and a vibrant biotech ecosystem, crucial for Cytek's growth and innovation.
Cytek Biosciences has established a significant global presence with direct operations and distribution networks across North America, Europe, and the Asia-Pacific region. Key functions supported globally include sales, marketing, customer service, technical and application support, and R&D collaborations, ensuring worldwide access to their advanced cell analysis technologies and expertise.
47215 Mission Falls Court
Fremont
CA
USA
Address: Entrada 232, 1114 AA Amsterdam-Duivendrecht
To provide localized support and expand Cytek's footprint in the diverse and growing life sciences research and clinical sectors within the EMEA region.
Address: Sumitomo Fudosan Shibakoen First Bldg. 8F, 3-1-8 Shibakoen, Minato-ku
To address the sophisticated needs of the Japanese life sciences community and facilitate Cytek's growth in Japan and other strategic APAC markets.
Address: Building 5, No. 188 Fangqu Road, Waigaoqiao Pilot Free Trade Zone
To support the burgeoning biotechnology and pharmaceutical research landscape in China, providing direct access to Cytek's innovative technologies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cytek Biosciences' leadership includes:
Cytek Biosciences has been backed by several prominent investors over the years, including:
Based on publicly available information and recent news releases, there have been no major C-suite (CEO, CFO, COO, CTO level) executive hires or departures prominently announced for Cytek Biosciences within the last 12 months. The senior leadership team appears to have maintained stability.
Discover the tools Cytek Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cytek Biosciences typically uses a standard corporate email format. The most common structure observed is the first initial followed by the last name.
[first_initial][last]@cytekbio.com
Format
wjiang@cytekbio.com
Example
80%
Success rate
PR Newswire • May 8, 2024
Cytek Biosciences announced its financial results for the first quarter ended March 31, 2024. The company reported total revenue of $40.3 million and highlighted progress in its strategic initiatives and product adoption....more
Business Wire • February 27, 2024
Cytek announced the launch of a new cGMP-manufactured 14-color immunoprofiling assay, expanding its reagent portfolio and providing researchers with a comprehensive tool for deep immune cell analysis on its Full Spectrum Profiling systems....more
GlobeNewswire • January 8, 2024
Cytek provided preliminary unaudited revenue results, expecting full year 2023 revenue to be approximately $194 million, representing around 16% growth over 2022. This announcement was made ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cytek Biosciences, are just a search away.